Conflicting results on the efficacy of remdesivir in hospitalized Covid-19 patients: comment on the Adaptive Covid-19 Treatment Trial

Benzer Materyaller

• The widely promoted antimalarial drug hydroxychloroquine confers no mortality benefit in hospitalized patients with COVID-19: comment on the ‘Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19’
  Yazar:: Liuzzo, Giovanna, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19
  Yazar:: Volpe, Massimo, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• COVID 19: in the eye of the cytokine storm
  Yazar:: Liuzzo, Giovanna, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Re-purposed antiviral drugs without a purpose in COVID-19: a valuable lesson for clinicians
  Yazar:: Liuzzo, Giovanna, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• Response to COVID-19 in a large academic Centre in South Africa: The cohesive response to COVID-19 of the Groote Schuur Hospital in Cape Town is discussed by the Chair of Medicine at the hospital and University of Cape Town
  Yazar:: Ntusi, Ntobeko A B
  Baskı/Yayın Bilgisi: (2020)